Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Adamis Pharmaceuticals Company

ADMP
US00547W2089
A1XA2F

Price

0.51
Today +/-
+0
Today %
+0 %
P

Adamis Pharmaceuticals stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Adamis Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Adamis Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Adamis Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Adamis Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Adamis Pharmaceuticals Stock Price History

DateAdamis Pharmaceuticals Price
11/8/20230.51 undefined
11/7/20230.50 undefined

Adamis Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Adamis Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Adamis Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Adamis Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Adamis Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Adamis Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Adamis Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Adamis Pharmaceuticals’s growth potential.

Adamis Pharmaceuticals Revenue, EBIT and net profit per share

DateAdamis Pharmaceuticals RevenueAdamis Pharmaceuticals EBITAdamis Pharmaceuticals Net Income
2026e148.02 M undefined2.12 M undefined1.97 M undefined
2025e71.34 M undefined3.75 M undefined3.43 M undefined
2024e35.07 M undefined6.75 M undefined6.12 M undefined
2023e17.53 M undefined-10.54 M undefined-7.65 M undefined
20224.76 M undefined-25.06 M undefined-26.48 M undefined
20212.21 M undefined-32.07 M undefined-45.83 M undefined
20202.78 M undefined-31.68 M undefined-49.39 M undefined
201922.11 M undefined-29.03 M undefined-27.51 M undefined
201815.09 M undefined-39.45 M undefined-39.01 M undefined
201713.07 M undefined-24.69 M undefined-25.54 M undefined
20166.47 M undefined-25.2 M undefined-20.81 M undefined
20150 undefined-13.85 M undefined-13.57 M undefined
20140 undefined-8.1 M undefined-9.32 M undefined
20130 undefined-4.4 M undefined-8.16 M undefined
20120 undefined-3.22 M undefined-7.19 M undefined
20110 undefined-4.82 M undefined-4.92 M undefined
20100 undefined-6.24 M undefined-6.98 M undefined
2009290,000 undefined-3.98 M undefined-6.71 M undefined
20080 undefined-1.32 M undefined-1.53 M undefined
20070 undefined-1.83 M undefined-1.93 M undefined
20062.66 M undefined-4.68 M undefined9.67 M undefined
200512.2 M undefined-5.36 M undefined-5.01 M undefined
20042.03 M undefined-14 M undefined-28.15 M undefined
20031.62 M undefined-13.89 M undefined-13.53 M undefined

Adamis Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
1993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023e2024e2025e2026e
0010001101121220000000006131522224173571148
-----------100.00500.00-83.33----------116.6715.3846.67-90.91-100.00325.00105.88102.86108.45
--100.00----100.00-100.00100.0050.0091.67100.00---------16.6738.4633.3327.27-150.00-200.00-25.00----
0010000101111120000000001556-3-4-10000
-2-2-1-3-4-8-9-11-17-15-13-14-5-4-1-1-3-6-4-3-4-8-13-25-24-39-29-31-32-25-10632
---100.00----900.00-1,100.00--1,500.00-1,300.00-700.00-41.67-200.00----------416.67-184.62-260.00-131.82-1,550.00-1,600.00-625.00-58.8217.144.231.35
-2-2-2-4-7-7-9-11-19-15-13-28-59-1-1-6-6-4-7-8-9-13-20-25-39-27-49-45-26-7631
---100.0075.00-28.5722.2272.73-21.05-13.33115.38-82.14-280.00-111.11-500.00--33.3375.0014.2912.5044.4453.8525.0056.00-30.7781.48-8.16-42.22-73.08-185.71-50.00-66.67
00000000000000000.020.050.080.080.10.150.190.250.410.560.761.112.062.140000
----------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Adamis Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Adamis Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (k)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (k)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022
                                                           
1.130.43.825.299.38.8911.7815.319.8523.6311.348.712.123.81.830.130.291.240.0105.43.774.084.0917.3219.278.816.8623.221.08
00000000000.160.891.070.06000.010000000.810.831.161.881.090.821.05
00000000000000000000000000005.080.03
000000.050000000.2600000000000.941.823.282.063.120.421.24
0.060.010.150.351.011.381.030.860.840.610.350.281.080.280.270.030.030.290.030.350.010.180.071.231.492.071.121.465.665.87
1.190.413.975.6410.3110.3212.8116.1710.6924.2411.859.884.534.142.10.160.331.530.040.355.413.954.157.0721.4625.7813.8712.5235.29.27
0.040.01-0.01-0.03-0.052.462.62.181.731.641.020.660.500000000.090.080.064.96.569.8713.5411.132.991.61
0.050.050.072.0912.496.75.520.667.470.980.881.30000000000.130.090.040.050.050000
000000000000000000000000000000
00000001.531.520.280.260.780.200000009.618.747.7718.1415.6913.2111.136.2900
0000000000.921.011.03000000000007.647.647.647.640.8700
00.08000000.710.960.330.330.231.230000.350.20.130000001.81.650.050.110.05
0.090.140.062.0612.449.168.125.0811.684.153.541.930000.350.20.1309.78.957.9230.7229.9432.5733.9618.343.091.66
1.280.554.037.722.7519.4820.9321.2522.3728.3915.3513.886.464.142.10.160.681.730.170.3515.1112.912.0737.7951.458.3547.8330.8738.310.93
                                                           
6.626.6313.822.344.1944.3655.3769.7490.1496.1497.29000000.010.010.010.010000000.010.010.020.17
00000000000120.25125.55125.7125.75125.2314.6124.4828.0533.6458.3264.9678.34113.74153.55199.7213.52233.4303.96303.75
-5.46-8-10.16-14.94-22.83-30.19-39.49-50.91-70.38-85.62-99.15-127.3-132.31-122.64-124.57-126.1-18.89-25.87-30.78-37.98-46.13-55.45-69.02-88.46-114-153-180.52-229.91-278.09-304.56
0000050-40-30801028030028000000000000000000
00020-100000000000000000000000000
1.16-1.373.647.3821.3514.2215.8418.819.8410.53-1.58-6.75-6.483.061.18-0.87-4.27-1.38-2.72-4.3312.199.519.3225.2839.5546.733.013.525.89-0.65
0.10.340.190.270.711.550.480000.781.691.740.1800.071.561.262.022.430.670.790.52.152.924.174.273.493.757.94
0.020.050.190.040.190.160.351.582.042.131.242.732.380.540.40.191.610.490.570.860.440.540.692.083.373.792.8711.965.692.16
01000.50.250000.830.831.20.290000000.211.42.071.560.050.011.010.120.11.781.3
00.540000.41.150.55000000001.781.360.31.180.42003.86200000
0000000000004.980.050000000000.470.482.582.164.3700
0.121.930.380.311.42.361.982.132.042.962.855.629.390.770.40.264.953.112.894.682.933.42.758.618.7811.559.4219.9311.2211.4
000002.822.880.330000.720.260.320.510.7800000003.072.58000.8900
00000000000000000000000830490110110112.5300
000000.080.2200.4914.8814.0614.283.2800000000000005.326.441.190.19
000002.93.10.330.4914.8814.06153.540.320.510.7800000003.93.070.115.437.441.190.19
0.121.930.380.311.45.265.082.462.5317.8416.9120.6212.931.090.911.044.953.112.894.682.933.42.7512.5111.8511.6614.8527.3712.4211.58
1.280.564.027.6922.7519.4820.9221.2622.3728.3715.3313.876.454.152.090.170.681.730.170.3515.1212.9112.0737.7951.458.3647.8630.8738.310.94
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Adamis Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Adamis Pharmaceuticals's financial health and stability.

Assets

Adamis Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Adamis Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Adamis Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Adamis Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (k)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (k)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
199319941995199619971998199920002001200220032004200520062007200820092010201120122013null201420152016201720182019202020212022
-2-2-2-3-7-7-9-11-19-15-13-28-59-1-1-6-6-4-7-8-8-9-13-19-25-39-29-49-45-26
0000000000000000000000002332311
000000000000000000000000-4000000
01-100000015-1-1-15-1001000-2-200-30-605-10-1
00003000401153-1300320333123710719170
000000000000000000001,0001,000000000000
0000000000000000000000000000000
-2,000-1,000-2,000-3,000-3,000-7,000-9,000-9,000-13,0001,000-12,000-13,000-16,000-5,000-1,000-1,000-2,000-4,000-3,000-2,000-6,000-6,000-6,000-10,000-21,000-15,000-32,000-19,000-20,000-37,000-25,000
00000-200000000000000-10-10000-2-3-20-10
21-1-5-123-38-48-23010000000-10-10000-2-3-2003
21-1-5-126-29-48-1301000000000000000014
0000000000000000000000000000000
0000030-300004-3002002-1-1001-200310
006617011121550115000052025255102032371218570
006617311814601110-300252222224102130371219530
---------------------2.00-2.00-------1.00-5.00-
0000000000000000000000000000000
001-21008-315-130-61-1-100-1055-101130-10-116-22
-2.2-1.16-2.73-3.35-3.5-10.04-10.36-9.38-13.160.88-13.13-13.8-16.83-5.04-1.94-1.2-2-4.31-3.35-2.56-16.780-6.41-10.34-21.28-17.22-36.2-22.76-21.85-39.01-26.59
0000000000000000000000000000000

Adamis Pharmaceuticals stock margins

The Adamis Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Adamis Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Adamis Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Adamis Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Adamis Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Adamis Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Adamis Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Adamis Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Adamis Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Adamis Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Adamis Pharmaceuticals Margin History

Adamis Pharmaceuticals Gross marginAdamis Pharmaceuticals Profit marginAdamis Pharmaceuticals EBIT marginAdamis Pharmaceuticals Profit margin
2026e-30.1 %1.43 %1.33 %
2025e-30.1 %5.25 %4.81 %
2024e-30.1 %19.26 %17.45 %
2023e-30.1 %-60.14 %-43.64 %
2022-30.1 %-526.88 %-556.72 %
2021-211.14 %-1,451.97 %-2,074.91 %
2020-127.87 %-1,140.96 %-1,778.84 %
201930.03 %-131.3 %-124.42 %
201835.06 %-261.43 %-258.52 %
201743.23 %-188.91 %-195.41 %
201625.04 %-389.49 %-321.64 %
2015-30.1 %0 %0 %
2014-30.1 %0 %0 %
2013-30.1 %0 %0 %
2012-30.1 %0 %0 %
2011-30.1 %0 %0 %
2010-30.1 %0 %0 %
200910.34 %-1,372.41 %-2,313.79 %
2008-30.1 %0 %0 %
2007-30.1 %0 %0 %
200690.23 %-175.94 %363.53 %
200597.95 %-43.93 %-41.07 %
200497.04 %-689.66 %-1,386.7 %
200388.27 %-857.41 %-835.19 %

Adamis Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Adamis Pharmaceuticals earnings per share therefore indicates how much revenue Adamis Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Adamis Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Adamis Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Adamis Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Adamis Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Adamis Pharmaceuticals Revenue, EBIT and net profit per share

DateAdamis Pharmaceuticals Sales per ShareAdamis Pharmaceuticals EBIT per shareAdamis Pharmaceuticals Earnings per Share
2026e0.99 undefined0 undefined0.01 undefined
2025e0.48 undefined0 undefined0.02 undefined
2024e0.23 undefined0 undefined0.04 undefined
2023e0.12 undefined0 undefined-0.05 undefined
20222.22 undefined-11.7 undefined-12.37 undefined
20211.07 undefined-15.57 undefined-22.25 undefined
20202.5 undefined-28.58 undefined-44.56 undefined
201929.09 undefined-38.2 undefined-36.2 undefined
201826.95 undefined-70.45 undefined-69.66 undefined
201731.88 undefined-60.22 undefined-62.29 undefined
201625.88 undefined-100.8 undefined-83.24 undefined
20150 undefined-72.89 undefined-71.42 undefined
20140 undefined-54 undefined-62.13 undefined
20130 undefined-44 undefined-81.6 undefined
20120 undefined-40.25 undefined-89.88 undefined
20110 undefined-60.25 undefined-61.5 undefined
20100 undefined-124.8 undefined-139.6 undefined
200914.5 undefined-199 undefined-335.5 undefined
20080 undefined0 undefined0 undefined
20070 undefined0 undefined0 undefined
20060 undefined0 undefined0 undefined
20050 undefined0 undefined0 undefined
20040 undefined0 undefined0 undefined
20030 undefined0 undefined0 undefined

Adamis Pharmaceuticals business model

Adamis Pharmaceuticals Corp is a biotechnology company based in the USA that specializes in the development of pharmaceuticals and medical devices. The company was founded in 2006 and is headquartered in San Diego, California. History: Adamis Pharmaceuticals was founded by Dr. Dennis J. Carlo, an experienced pharmaceutical executive with over 35 years of industry experience. The company initially focused on the development of therapeutics for the treatment of allergies and respiratory diseases. Over the years, the company has expanded its portfolio and specialized in the development of drugs for the treatment of anaphylaxis, asthma, and prostate cancer, as well as medical devices for drug delivery. Business model: Adamis Pharmaceuticals focuses on the development of novel drugs and medical devices that can improve patients' lives. The company seeks opportunities to meet unmet medical needs in existing therapy areas. Adamis collaborates closely with leading medical institutions and research facilities to develop and market a portfolio of innovative products. Various divisions: The company has various divisions, including: 1. Allergy/Respiratory: Adamis Pharmaceuticals has developed a broad portfolio of therapeutic agents for the treatment of allergies and respiratory diseases. The company has also developed a patented device called Symjepi, which is used to treat anaphylaxis, a life-threatening allergic reaction. This device also allows untrained individuals to self-treat in an anaphylaxis situation. 2. Oncology: Adamis Pharmaceuticals has developed a novel drug called TeloBlast®, which is used to treat prostate cancer. TeloBlast® targets telomerase, which is upregulated in many types of cancer. The company intends to develop additional drugs for the treatment of cancer in the future. 3. CNS: Adamis Pharmaceuticals has also developed innovative drugs for the treatment of CNS (central nervous system) disorders. The company plans to bring several new drugs for the treatment of neurological disorders to the market by 2022. 4. Medical devices: Adamis Pharmaceuticals has developed a range of patented medical devices, including the ZIM high-pressure injection pump, which allows doctors and nurses to administer medications quickly and accurately. Products: Adamis Pharmaceuticals' products include: 1. Symjepi: A patented device for the treatment of anaphylaxis. 2. TeloBlast®: A novel drug for the treatment of prostate cancer. 3. ZIM high-pressure injection pump: A patented medical device for drug administration. 4. Fluticasone/Salmeterol: An inhalable combination drug for the treatment of asthma and COPD (chronic obstructive pulmonary disease). Adamis Pharmaceuticals is an innovative biotechnology company specializing in the development of pharmaceuticals and medical devices. The company aims to meet unmet medical needs and improve patients' lives. With a broad portfolio of products and a strong commitment to research and development, Adamis Pharmaceuticals is well positioned to continue growing in the future. Adamis Pharmaceuticals is one of the most popular companies on Eulerpool.com.

Adamis Pharmaceuticals Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Adamis Pharmaceuticals Revenue by Segment

Segmente20192017
Sterile13.5 M USD-
Sterile Formulations-7.89 M USD
Non-Sterile Formulations-5.18 M USD
Non-Sterile4.86 M USD-
Outsourced Manufacturing3.76 M USD-

Adamis Pharmaceuticals SWOT Analysis

Strengths

Adamis Pharmaceuticals Corp has a strong product portfolio consisting of various innovative medications, covering a wide range of therapeutic areas. This diversification ensures a stable revenue stream and reduces dependency on a single product or market.

The company has a robust research and development (R&D) pipeline, consistently introducing new drugs to the market. This helps Adamis Pharmaceuticals stay competitive and adapt to changing market dynamics.

Adamis Pharmaceuticals has established strong relationships with key stakeholders, including healthcare providers, distributors, and insurance companies. These partnerships provide the company with increased market access and enhance its distribution capabilities.

Weaknesses

One of the weaknesses of Adamis Pharmaceuticals is its high dependence on external suppliers for raw materials and active pharmaceutical ingredients (APIs). Any disruption in the supply chain can have a negative impact on production and lead to delays in delivering products to the market.

The company has a relatively small market share compared to some of its larger competitors. This may limit its bargaining power and ability to influence pricing and reimbursement negotiations with payers.

Limited presence in international markets is another weakness of Adamis Pharmaceuticals. Expansion into global markets can provide opportunities for revenue growth, but it also exposes the company to additional regulatory and operational challenges.

Opportunities

The increasing demand for personalized medicine and targeted therapies presents an opportunity for Adamis Pharmaceuticals to develop innovative products tailored to individual patients' needs. This can help the company position itself as a leader in precision medicine.

Partnerships and collaborations with academic institutions and research organizations can provide Adamis Pharmaceuticals with access to cutting-edge technologies and expertise. This can accelerate its R&D efforts and enable the development of breakthrough drugs.

Advancements in healthcare infrastructure and a growing aging population create a larger market for pharmaceutical companies. Adamis Pharmaceuticals can tap into this expanding market by introducing new treatments for age-related diseases and conditions.

Threats

Intense competition from both established pharmaceutical companies and emerging biotech firms poses a threat to Adamis Pharmaceuticals. The industry is characterized by rapid technological advancements and evolving regulatory landscape, making it challenging to maintain a competitive edge.

Changes in government regulations can significantly impact the pharmaceutical industry. Adamis Pharmaceuticals must continually monitor and adapt to evolving regulations to ensure compliance and minimize potential disruptions.

The possibility of patent expirations for key drugs in Adamis Pharmaceuticals' portfolio creates the risk of generic competition. This can lead to a decline in market share and revenue if the company fails to successfully introduce new patented products.

Adamis Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Adamis Pharmaceuticals historical P/E ratio, EBIT multiple, and P/S ratio

Adamis Pharmaceuticals shares outstanding

The number of shares was Adamis Pharmaceuticals in 2023 — This indicates how many shares 2.141 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Adamis Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Adamis Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Adamis Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Adamis Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Adamis Pharmaceuticals stock splits

In Adamis Pharmaceuticals's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Adamis Pharmaceuticals.

Adamis Pharmaceuticals shareholders

%
Name
Stocks
Change
Date
4.32312 % The Vanguard Group, Inc.6,483,9453,25712/31/2022
1.84542 % BlackRock Institutional Trust Company, N.A.2,767,809-1,11012/31/2022
0.88454 % Geode Capital Management, L.L.C.1,326,654-76,37512/31/2022
0.46169 % Carlo (Dennis J)692,45907/6/2022
0.31695 % State Street Global Advisors (US)475,373012/31/2022
0.17229 % Tower Research Capital LLC258,40988,39812/31/2022
0.16311 % Northern Trust Investments, Inc.244,634012/31/2022
0.15996 % Williams (Richard C)239,918150,0007/6/2022
0.15988 % Marguglio (David J)239,79007/6/2022
0.13462 % Moss (Ronald B)201,91107/6/2022
1
2
3
4
5
...
10

Adamis Pharmaceuticals Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Catalent Stock
Catalent
SupplierCustomer0,550,460,560,600,720,40
3M Co Stock
3M Co
SupplierCustomer0,090,15-0,120,540,840,46
Walgreens Boots Alliance Stock
Walgreens Boots Alliance
SupplierCustomer-0,44-0,450,640,540,320,21
1

Most common questions regarding Adamis Pharmaceuticals

What values and corporate philosophy does Adamis Pharmaceuticals represent?

Adamis Pharmaceuticals Corp represents a strong dedication to delivering innovative and high-quality healthcare solutions. The company's core values revolve around putting patients first and striving for excellence in all areas of operation. Adamis Pharmaceuticals Corp is committed to providing accessible and affordable medications to improve the lives of individuals worldwide. With a focus on constantly developing and advancing pharmaceutical products, the company aims to make a positive impact on the healthcare industry. By prioritizing innovation, quality, and patient-centered care, Adamis Pharmaceuticals Corp strives to establish itself as a trusted and reliable partner in the pharmaceutical market.

In which countries and regions is Adamis Pharmaceuticals primarily present?

Adamis Pharmaceuticals Corp is primarily present in the United States.

What significant milestones has the company Adamis Pharmaceuticals achieved?

Adamis Pharmaceuticals Corp has achieved several significant milestones. One notable accomplishment is the FDA approval of their flagship product, Symjepi, which is an epinephrine injection for the emergency treatment of allergic reactions. Additionally, the company has successfully launched other pharmaceutical products in the market, such as ZIMHI for opioid overdose and Tempol for COVID-19 treatment. Adamis Pharmaceuticals Corp has also established strategic partnerships and collaborations to expand their product pipeline and improve patient care. These achievements demonstrate the company's commitment to innovation and their dedication to addressing critical medical needs.

What is the history and background of the company Adamis Pharmaceuticals?

Adamis Pharmaceuticals Corp is a pharmaceutical company specializing in the development and commercialization of therapeutic products. Established in 2006, the company primarily focuses on developing treatments for respiratory disease, allergies, and opioid overdose. Adamis Pharmaceuticals Corp is recognized for its innovation and dedication in providing effective healthcare solutions to patients. With a strong portfolio of products and ongoing research and development efforts, the company strives to improve the lives of individuals worldwide. Adamis Pharmaceuticals Corp continues to uphold its commitment to delivering high-quality pharmaceuticals and is a prominent player in the healthcare industry.

Who are the main competitors of Adamis Pharmaceuticals in the market?

Adamis Pharmaceuticals Corp faces competition from several companies in the market. Some of its main competitors include Teva Pharmaceutical Industries Ltd., Mylan N.V., and GlaxoSmithKline plc. These companies also operate in the pharmaceutical industry, offering similar products and services. It is essential for Adamis Pharmaceuticals Corp to stay competitive by constantly innovating, developing new drugs, and maintaining high product quality. By closely monitoring its competitors and adapting its strategies accordingly, Adamis Pharmaceuticals Corp can strive to achieve a dominant position in the market and continue delivering value to its customers and stakeholders.

In which industries is Adamis Pharmaceuticals primarily active?

Adamis Pharmaceuticals Corp is primarily active in the healthcare and pharmaceutical industries.

What is the business model of Adamis Pharmaceuticals?

Adamis Pharmaceuticals Corp is a company with a business model focused on the development and commercialization of specialty pharmaceutical products. They aim to provide innovative and cost-effective treatment options for various medical conditions, including respiratory disease, allergy, and opioid overdose. Adamis Pharmaceuticals Corp seeks to leverage their expertise in drug delivery systems to develop and improve existing medications. With a commitment to meeting unmet medical needs, they strive to enhance patient outcomes and provide value to healthcare professionals and consumers alike.

What is the P/E ratio of Adamis Pharmaceuticals 2024?

The Adamis Pharmaceuticals P/E ratio is 0.18.

What is the P/S ratio of Adamis Pharmaceuticals 2024?

The Adamis Pharmaceuticals P/S ratio is 0.03.

What is the Quality Investing of Adamis Pharmaceuticals?

The Quality Investing for Adamis Pharmaceuticals is 6/10.

What is the revenue of Adamis Pharmaceuticals 2024?

The expected Adamis Pharmaceuticals revenue is 35.07 M USD.

How high is the profit of Adamis Pharmaceuticals 2024?

The expected Adamis Pharmaceuticals profit is 6.12 M USD.

What is the business model of Adamis Pharmaceuticals

Adamis Pharmaceuticals Corp is a US pharmaceutical company specializing in the development and marketing of innovative medications and biological therapies. The company operates in several divisions, including allergy and immunology products, pulmonology products, oncology products, and veterinary products. The company's business model includes partnerships and licensing agreements with other biopharmaceutical companies, as well as targeted marketing strategies and the use of modern technologies and digital tools to promote their products and services. The goal of the company is to expand its position in the biopharmaceutical market through strong partnerships and a targeted marketing strategy.

What is the Adamis Pharmaceuticals dividend?

Adamis Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does Adamis Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for Adamis Pharmaceuticals or the company does not pay out a dividend.

What is the Adamis Pharmaceuticals ISIN?

The ISIN of Adamis Pharmaceuticals is US00547W2089.

What is the Adamis Pharmaceuticals WKN?

The WKN of Adamis Pharmaceuticals is A1XA2F.

What is the Adamis Pharmaceuticals ticker?

The ticker of Adamis Pharmaceuticals is ADMP.

How much dividend does Adamis Pharmaceuticals pay?

Over the past 12 months, Adamis Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Adamis Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Adamis Pharmaceuticals?

The current dividend yield of Adamis Pharmaceuticals is .

When does Adamis Pharmaceuticals pay dividends?

Adamis Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Adamis Pharmaceuticals?

Adamis Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Adamis Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Adamis Pharmaceuticals located?

Adamis Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Adamis Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Adamis Pharmaceuticals from 10/10/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/10/2024.

When did Adamis Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/10/2024.

What was the dividend of Adamis Pharmaceuticals in the year 2023?

In the year 2023, Adamis Pharmaceuticals distributed 0 USD as dividends.

In which currency does Adamis Pharmaceuticals pay out the dividend?

The dividends of Adamis Pharmaceuticals are distributed in USD.

All fundamentals about Adamis Pharmaceuticals

Our stock analysis for Adamis Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Adamis Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.